Prevalence, Risk Factors, Prognosis, and Management of Pericardial Effusion in COVID-19

Author:

Saraç İbrahim1ORCID,Aydın Sidar Şiyar1,Özmen Murat1,Doru Halil İbrahim2,Tonkaz Gökhan3,Çırçır Melike Nur2ORCID,Akpınar Furkan2,Zengin Onur2,Delice Orhan2,Aydınyılmaz Faruk1

Affiliation:

1. Department of Cardiology, Erzurum City Hospital, Erzurum 25010, Turkey

2. Department of Emergency Medicine, Erzurum City Hospital, Erzurum 25010, Turkey

3. Department of Radiology, Giresun University Research Hospital, Giresun 28200, Turkey

Abstract

Background: There is limited data in the literature about the clinical importance and prognosis of pericardial effusion (PE) in patients discharged after recovering from COVID-19, but large-scale studies have yet to be available. This study investigated the prevalence, risk factors, prognosis, late clinical outcomes, and management of PE in COVID-19. Materials and Methods: Between August 2020 and March 2021, 15,689 patients were followed up in our pandemic hospital due to COVID-19. Patients with positive polymerase chain reaction (PCR) test results and PE associated with COVID-19 in computed tomography (CT) were included in the study. The patients were divided into three groups according to PE size (mild, moderate, and large). Transthoracic echocardiography (TTE) records, laboratory data, clinical outcomes, and medical treatments of patients discharged from the hospital were retrospectively reviewed. Results: According to the PE size (mild, moderate, large) of 256 patients with PE at admission or discharge, the mean age was 62.17 ± 16.34, 69.12 ± 12.52, and 72.44 ± 15.26, respectively. The mean follow-up period of the patients was 25.2 ± 5.12 months. Of the patients in the study population, 53.5% were in the mild group, 30.4% in the moderate group, and 16.1% in the large group. PE became chronic in a total of 178 (69.6%) patients at the end of the mean three months, and chronicity increased as PE size increased. Despite the different anti-inflammatory treatments for PE in the acute phase, similar chronicity was observed. In addition, as the PE size increased, the patients’ frequency of hospitalization, complications, and mortality rates showed statistical significance between the groups. Conclusions: The clinical prognosis of patients presenting with PE was quite poor; as PE in size increased, cardiac and noncardiac events and mortality rates were significantly higher. Patients with large PE associated with COVID-19 at discharge should be monitored at close intervals due to the chronicity of PE and the increased risk of tamponade.

Publisher

MDPI AG

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics

Reference34 articles.

1. COVID-19 pandemic: From origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management;Ochani;Infez. Med.,2021

2. Three waves changes, new variant strains, and vaccination effect against COVID-19 pandemic;Nayel;Int. J. Biol. Macromol.,2022

3. COVID-19: Pulmonary and extra pulmonary manifestations;Elrobaa;Front. Public Health,2021

4. Coronavirus disease 2019 (COVID-19) and severe pericardial effusion: From pathogenesis to management: A case report based systematic review;Pouramini;Curr. Probl. Cardiol.,2022

5. The relationship between pericardial effusion and pulmonary involvement, prognosis, mortality in COVID-19 patients;Tonkaz;Kardiologiia,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3